These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. [Cisplatin and carboplatin in the treatment of malignant lymphoma and multiple myeloma]. Adam Z; Mayer J; Hájek R Vnitr Lek; 1994 Dec; 40(12):790-800. PubMed ID: 7839634 [TBL] [Abstract][Full Text] [Related]
64. [Hematology 2010]. Dreyling M; Subklewe M; Braess J; Spiekermann K Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1322-5. PubMed ID: 20556691 [No Abstract] [Full Text] [Related]
65. Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. Osborne CK; Evens A Oncology (Williston Park); 2011 Dec; 25(14):1422-4, 1426. PubMed ID: 22329194 [No Abstract] [Full Text] [Related]
66. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation]. Imataki O; Aoyama T; Tamai Y; Kawakami K Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379 [TBL] [Abstract][Full Text] [Related]
67. Novel combination approaches for myeloma. Lonial S; Nooka AK Hematology Am Soc Hematol Educ Program; 2015; 2015():286-93. PubMed ID: 26637735 [No Abstract] [Full Text] [Related]
68. Bortezomib data show improved survival in patients with relapsed multiple myeloma. Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202 [No Abstract] [Full Text] [Related]
70. [Carfilzomib in multiple myeloma relapses]. Bay JO Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287 [No Abstract] [Full Text] [Related]
71. Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition. Clin Adv Hematol Oncol; 2021 Mar; 19 Suppl 11(3):1-20. PubMed ID: 33843915 [No Abstract] [Full Text] [Related]
73. Lymphoid malignancies: a decade and a half of dramatic improvements in outcome. Zelenetz AD Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S126-7. PubMed ID: 18952542 [No Abstract] [Full Text] [Related]
74. Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. Barr PM Clin Adv Hematol Oncol; 2021 Mar; 19 Suppl 11(3):17-19. PubMed ID: 33843916 [No Abstract] [Full Text] [Related]
75. Recent advances in the treatment of leukemia, lymphoma, and myeloma. [Review of Selected Presentations From the 52nd American Society of Hematology Annual Meeting and Exposition. December 4–7, 2010. Orlando, Florida]. Cheson BD Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 7):1-24. PubMed ID: 21558999 [No Abstract] [Full Text] [Related]
77. [Myelomatosis--toward a breakthrough? The Danish Society of Hematology]. Johnsen HE Ugeskr Laeger; 2000 Mar; 162(12):1712. PubMed ID: 10745659 [No Abstract] [Full Text] [Related]
78. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Barosi G; Merlini G; Billio A; Boccadoro M; Corradini P; Marchetti M; Massaia M; Tosi P; Palumbo A; Cavo M; Tura S Ann Hematol; 2012 Jun; 91(6):875-88. PubMed ID: 22476884 [TBL] [Abstract][Full Text] [Related]
79. Pomalidomide: when expectations are understated. Di Raimondo F; Conticello C Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940 [No Abstract] [Full Text] [Related]
80. Researchers debate best use of stem cell transplants in patients with multiple myeloma. Rowan K J Natl Cancer Inst; 2009 Dec; 101(23):1608-11. PubMed ID: 19910555 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]